Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

New Developments in Ion Channel Biology and Drug Discovery

New Developments in Ion Channel Biology and Drug Discovery

Tuesday, September 26, 2006

Midtown Executive and Chemist's Club - Priestley Room, 2nd floor

Organizers: Mark Bowlby and John Dunlop, Wyeth Research

: John Dunlop, Wyeth Research; Terry Snutch, University of British Columbia, Vancouver; Alan Wickenden, J&J PR&D; Mark Bowlby, Wyeth Research; John Wemmie, University of Iowa

Ion channels remain a relatively underexploited target class in terms of drug discovery yet significant advances have been made in understanding the basic biology of many therapeutically relevant channels. This symposium will discuss the latest developments in ion channel drug discovery.


1:00 – 1:10 John Dunlop, Wyeth Research, Princeton, NJ, Introduction: "New Developments in Ion Channel Biology and Drug Discovery."

1:10 – 2:00 Terry Snutch, University of British Columbia, Vancouver, Canada, "Targeting N-type and T-type Calcium Channels for the Treatment of Pain."

2:00 – 2:50 Alan Wickenden, J&J PR&D, San Diego, CA, "TRPV1 and Pain."

2:50 – 3:20 Coffee Break

3:20 – 4:10 Mark Bowlby, Wyeth Research, Princeton, NJ, "Nav Channels as Targets for Chronic Pain."

4:10 – 5:00 John Wemmie, University of Iowa, Iowa City, IA, "Inhibiting ASIC1a Reduces Anxiety-related Behavior."

5:00 Adjourn